Menu UF Health Home Menu
 

Amir M. Emtiazjoo, MD, MSc

Amir M. Emtiazjoo, MD, MSc
Assistant Professor of Medicine

Email: Amir.Emtiazjoo@medicine.ufl.edu 

TEL: 352.273.8737
FAX: 352.273.9154

 

 

Degree/Program

Institution

Field/Specialty

MD Tehran University of Medical Sciences
Residency  University of California at San Francisco (UCSF)-Fresno Internal Medicine
Fellowship Indiana University School of Medicine Pulmonary and Critical Care Medicine
Fellowship Stanford University Lung and Heart-Lung Transplant
MSc McGill University Molecular Biology

 Clinical Interests:

  • Lung & Heart-lung transplantation
  • Advanced Lung Disease
  • Antibody mediated lung allograft rejection
  • Management of highly sensitized Lung transplant candidates

Research Interests:

  • Dr. Emtiazjoo’s research focuses on lung transplant immunology. He has studied the role of humoral immunity (alloimmunity & atuoimmunity) in development of Primary Graft Dysfunction (PGD) and allograft dysfunction post lung transplantation.

Honors and Awards:

  • The American College of Chest Physicians (ACCP), Best case presentation. CHEST 2011, Honolulu, HI (10/2011)
  • Montreal Centre for Experimental Therapeutics in Cancer (MCETC). Young Investigator Research Grant, McGill University, Montreal, Quebec, Canada (06/2002-06/2044)

Publications:

Peer Reviewed Original Publications

  •  Shah RJ, K Rothaar, Emtiazjoo AM, S Frye, JM Diamond, E Cantu III , DJ Lederer, VN Lama, J Orens, P Shah, A Weinacker, G Dhillon , S Bhorade , KM Wille, LB Ware, SM Palmer, L Snyder, M Hartwig , M Crespo, J McDyer, DS WilkesJD Christie. The role of antibodies to collagen V in the development of Primary Graft Dysfunction. JHLT (submitted)
  • Biswas A, Ataya A, Chandrashekaran S, Salgado JC, Machuca T, Emtiazjoo AM. A 42-year-old woman with Anemia, Shock and Ischemic Stroke After Lung Transplantation. CHEST (accepted-in press).
  • Ataya A, Biswas A, Chandrashekaran S, Salgado JC, Goldstein SS, Emtiazjoo AM. A 48-Year-Old Man with Leukopenia, Jaundice, and Skin Rash After Lung Transplantation. CHEST 2016 Dec;150(6):e167-e170
  • Shah RJ, K Rothaar, Emtiazjoo AM, S Frye, JM Diamond, E Cantu III , DJ Lederer, VN Lama, J Orens, P Shah, A Weinacker, G Dhillon , S Bhorade , KM Wille, LB Ware, SM Palmer, L Snyder, M Hartwig , M Crespo, J McDyer, DS WilkesJD Christie. The role of antibodies to collagen V in the development of Primary Graft Dysfunction. JHLT (submitted)
  • Emtiazjoo AM, Shah RJ, S Frye, JM Diamond, E Cantu III , DJ Lederer, VN Lama, J Orens, P Shah, A Weinacker, S Bhorade , KM Wille, LB Ware, SM Palmer, L Snyder, M Hartwig , M Crespo, J McDyer, DS WilkesJD Christie. Plasma Complement C5a is Associated with Risk of Primary Graft and Mortality after Lung Transplantation Dysfunction. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1564-7
  • Vittal R, Fisher A, Brown K, Mickller E, Gu H, Emtiazjoo AM, Cummings O,Wilkes DS. Type V Collagen Induced Tolerance Suppresses Collagen Deposition TGF-beta and Associated Transcripts in Pulmonary Fibrosis. PLoS One 2013 Oct 21;8(10):e76451
  • Emtiazjoo AM, Wilkes DS. Humoral Immunity and Development of Obliterative Bronchiolitis Post Lung Transplantation – is there a Link? Am J Respir Cell Mol Biol2013 Feb;48(2):145-9
  • Van Der Veer J, Lewis R, Emtiazjoo AM, Wheat LJ, Allen S, Hage C. Cross-reactivity in the Platelia™ Aspergillus enzyme immunoassay caused by blastomycosis. Med Mycol. 2012 May;50(4):396-8)  
  • Emtiazjoo AM. Negatively charged amino acids flanking the LXXLL motifs decrease the interaction between co-activators and estrogen receptor alpha, but not beta, using Bioluminescence Resonance Energy Transfer (BRET). Master’s thesis, McGill University, Montreal, Canada.

Editorial 

  • Emtiazjoo AM, Shillings RA. Preventing the NET Negative in Primary Graft Dysfunction. Am J Respire Crit Care Med. 2015 Feb 15;191(4):368-9

Book Chapter

  • Salgado JC, Chandrachekaran S, Emtiazjoo AM. Intensive Care Unit Management of Lung Transplant patients. Textbook of Critical Care, Vincent JL 7th edition, Elsevier2017 Jan; 158:1099-1105.